Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) has issued a profit forecast, expecting a net profit of 1.43 billion yuan for the year 2024, an increase of 121.99% year-on-year.
Aeris (688578.SH) released an announcement, stating that the company expects to achieve a net profit attributable to the owner of the parent company in 2024...
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company expects to achieve a net profit attributable to the owners of the parent company of 1.43 billion yuan in 2024, a year-on-year increase of 121.99%.
The main reasons for the performance growth are: The company's core product, Fumitelanib mesylate tablets, was renewed and included in the national medical insurance catalog, leading to continuous growth in sales revenue. At the same time, the company has effectively implemented a number of cost reduction and efficiency improvement measures, strict control over various costs and expenses, resulting in a significant improvement in the company's performance.
Related Articles
On May 9th, Gui Chuang Tong Qiao (02190) spent HK$958,500 to repurchase 50,000 shares.
Jiangsu Boqian New Materials Stock (605376.SH) shareholders Zhongzhi Ju Cheng reduced their holdings by 0.42%.
Guotai Junan International (01788) spent 535,300 Hong Kong dollars on May 9 to repurchase 500,000 shares.
On May 9th, Gui Chuang Tong Qiao (02190) spent HK$958,500 to repurchase 50,000 shares.
Jiangsu Boqian New Materials Stock (605376.SH) shareholders Zhongzhi Ju Cheng reduced their holdings by 0.42%.
Guotai Junan International (01788) spent 535,300 Hong Kong dollars on May 9 to repurchase 500,000 shares.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
